BridgeBio Pharma Total Liabilities 2018-2026 | BBIO
BridgeBio Pharma total liabilities from 2018 to 2026. Total liabilities can be defined as the total value of all possible claims against the corporation.
- BridgeBio Pharma total liabilities for the quarter ending June 30, 2026 were $3.722B, a 30.23% increase year-over-year.
- BridgeBio Pharma total liabilities for 2025 were $3.012B, a 26.71% increase from 2024.
- BridgeBio Pharma total liabilities for 2024 were $2.377B, a 25.81% increase from 2023.
- BridgeBio Pharma total liabilities for 2023 were $1.889B, a 1.23% increase from 2022.
|
BridgeBio Pharma Annual Total Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $3,012 |
| 2024 | $2,377 |
| 2023 | $1,889 |
| 2022 | $1,866 |
| 2021 | $1,880 |
| 2020 | $597 |
| 2019 | $158 |
| 2018 | $88 |
| 2017 | $0 |
|
BridgeBio Pharma Quarterly Total Liabilities (Millions of US $) |
|
|---|---|
| 2026-06-30 | $3,722 |
| 2026-03-31 | $3,639 |
| 2025-12-31 | $3,012 |
| 2025-09-30 | $2,921 |
| 2025-06-30 | $2,858 |
| 2025-03-31 | $2,520 |
| 2024-12-31 | $2,377 |
| 2024-09-30 | $1,884 |
| 2024-06-30 | $1,876 |
| 2024-03-31 | $1,887 |
| 2023-12-31 | $1,889 |
| 2023-09-30 | $1,850 |
| 2023-06-30 | $1,854 |
| 2023-03-31 | $1,839 |
| 2022-12-31 | $1,866 |
| 2022-09-30 | $1,857 |
| 2022-06-30 | $1,876 |
| 2022-03-31 | $1,854 |
| 2021-12-31 | $1,880 |
| 2021-09-30 | $1,520 |
| 2021-06-30 | $1,539 |
| 2021-03-31 | $1,483 |
| 2020-12-31 | $597 |
| 2020-09-30 | $572 |
| 2020-06-30 | $580 |
| 2020-03-31 | $541 |
| 2019-12-31 | $158 |
| 2019-09-30 | $119 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-09-30 | $0 |
| 2017-12-31 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $13.352B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |